<?xml version="1.0" encoding="UTF-8"?>
<document>
<type>mainstream</type>
<forum>http://www.mideasttime.com/feed</forum>
<forum_title>Mideast Time</forum_title>
<discussion_title>Analysts Set Cerulean Pharma Inc. (NASDAQ:CERU) PT at $6.80</discussion_title>
<language>english</language>
<gmt_offset></gmt_offset>
<topic_url>http://www.mideasttime.com/analysts-set-cerulean-pharma-inc-nasdaqceru-pt-at-6-80/1212617/</topic_url>
<topic_text>
Tweet 
Cerulean Pharma Inc. (NASDAQ:CERU) has received a consensus rating of “Buy” from the nine brokerages that are covering the company. Four investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $9.00. 
A number of brokerages recently weighed in on CERU. Canaccord Genuity restated a “buy” rating and issued a $20.00 price objective (down from $29.00) on shares of Cerulean Pharma in a report on Sunday. Wedbush lowered shares of Cerulean Pharma from an “outperform” rating to a “neutral” rating in a report on Thursday. Roth Capital restated a “buy” rating and issued a $2.50 price objective (down from $9.00) on shares of Cerulean Pharma in a report on Thursday. Leerink Swann lowered shares of Cerulean Pharma from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $8.00 to $1.50 in a report on Thursday. Finally, Janney Montgomery Scott lowered shares of Cerulean Pharma from a “buy” rating to a “neutral” rating in a report on Thursday. 
Shares of Cerulean Pharma ( NASDAQ:CERU ) opened at 1.15 on Friday. The stock’s market cap is $31.49 million. The company has a 50 day moving average price of $2.56 and a 200-day moving average price of $2.51. Cerulean Pharma has a 12 month low of $0.95 and a 12 month high of $5.20. 
Cerulean Pharma (NASDAQ:CERU) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.08. On average, equities research analysts predict that Cerulean Pharma will post ($1.59) earnings per share for the current year. 
Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.   Cerulean Pharma Inc.   Cerulean Pharma Inc.  
</topic_text>
<spam_score>0.00</spam_score>
<post_num>1</post_num>
<post_id>post-1</post_id>
<post_url>http://www.mideasttime.com/analysts-set-cerulean-pharma-inc-nasdaqceru-pt-at-6-80/1212617/</post_url>
<post_date>20160822</post_date>
<post_time>0749</post_time>
<username>Masoud Bidgoli</username>
<post>
Tweet 
Cerulean Pharma Inc. (NASDAQ:CERU) has received a consensus rating of “Buy” from the nine brokerages that are covering the company. Four investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $9.00. 
A number of brokerages recently weighed in on CERU. Canaccord Genuity restated a “buy” rating and issued a $20.00 price objective (down from $29.00) on shares of Cerulean Pharma in a report on Sunday. Wedbush lowered shares of Cerulean Pharma from an “outperform” rating to a “neutral” rating in a report on Thursday. Roth Capital restated a “buy” rating and issued a $2.50 price objective (down from $9.00) on shares of Cerulean Pharma in a report on Thursday. Leerink Swann lowered shares of Cerulean Pharma from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $8.00 to $1.50 in a report on Thursday. Finally, Janney Montgomery Scott lowered shares of Cerulean Pharma from a “buy” rating to a “neutral” rating in a report on Thursday. 
Shares of Cerulean Pharma ( NASDAQ:CERU ) opened at 1.15 on Friday. The stock’s market cap is $31.49 million. The company has a 50 day moving average price of $2.56 and a 200-day moving average price of $2.51. Cerulean Pharma has a 12 month low of $0.95 and a 12 month high of $5.20. 
Cerulean Pharma (NASDAQ:CERU) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.08. On average, equities research analysts predict that Cerulean Pharma will post ($1.59) earnings per share for the current year. 
Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.   Cerulean Pharma Inc.   Cerulean Pharma Inc.  
</post>
<signature>

</signature>
<external_links>

</external_links>
<country>EU</country>
<main_image>http://www.mideasttime.com/logos/cerulean-pharma-inc-logo.jpg</main_image>
</document>
